C-Peptide Levels Are Associated With Mortality and Cardiovascular Mortality in Patients Undergoing Angiography
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: C-peptide is a proinsulin cleavage product released from the pancreas in amounts equimolar to insulin, and elevated levels of C-peptide have been found in patients with insulin resistance and early type 2 diabetes mellitus. Recent data suggest that C-peptide could play a causal role in the pathophysiology of vascular disease, but nothing is known about the prognostic value of C-peptide concentrations in the circulation. RESEARCH DESIGN AND METHODS: We examined whether C-peptide is associated with cardiovascular and total mortality in 2,306 patients from the Ludwigshafen Risk and Cardiovascular Health Study who underwent coronary angiography at baseline (1997–2000). RESULTS: During a mean follow-up of 7.6 years, 440 deaths (19.1%) occurred, 252 (10.9%) of which were due to cardiovascular causes. Age- and sex-adjusted hazard ratios (HRs) in the third compared with the first tertile of C-peptide were 1.46 (95% CI 1.15–1.85; P = 0.002) for all cause and 1.58 (1.15–2.18; P = 0.005) for cardiovascular mortality. After further adjustment for common risk factors as well as markers of glucose metabolism, these HRs remained significant at 1.46 (1.10–1.93; P = 0.008) and 1.55 (1.07–2.24; P = 0.022), respectively. Moreover, patients in higher tertiles of C-peptide exhibited higher levels of markers of endothelial dysfunction and atherosclerosis as well as a more severe extent of coronary lesions. CONCLUSIONS: In patients undergoing coronary angiography, C-peptide levels are independently associated with all cause and cardiovascular mortality as well as presence and severity of coronary artery disease. Further studies are needed to examine a potential causal role of C-peptide in atherogenesis in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s062 · Cited by 5,491
How to measure comorbiditya critical review of available methods
DEGROOT, V, BECKERMAN, H., LANKHORST, G., & BOUTER, L. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(02)00585-1 · Cited by 1,757
Ma, J., Li, H., Giovannucci, E., Mucci, L., Qiu, W., Nguyen, P. L., Gaziano, J. M., Pollak, M., & Stampfer, M. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70235-3 · Cited by 421 · cited 3×
“Several studies examined the predictive role of C-peptide in populations of patients with manifest diabetes or its association with mortality in cancer patients (12,13).”
Background
Cited by
A practical review of C-peptide testing in diabetes
Leighton, E., Sainsbury, C. A., & Jones, G. C. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0265-4 · Cited by 773
Implementing a reference measurement system for C-peptide: successes and lessons learned
Little, R. R., Wielgosz, R. I., Josephs, R., Kinumi, T., Takatsu, A., Li, H., Stein, D., & Burns, C. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.269274 · Cited by 383
Maddaloni, E., Bolli, G. B., Frier, B. M., Little, R. R., Leslie, R. D., Pozzilli, P., & Buzzetti, R. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14785 · Cited by 135
“the studies conducted in type 2 diabetes suggest that higher Cpeptide levels are associated with cardiovascular events and increased mortality.(126,127) These C-peptide data should be interpreted with cau-”
Background
Metadata
- Authors
- Marx, N., Silbernagel, G., Brandenburg, V., Burgmaier, M., Kleber, M. E., Grammer, T. B., Winkelmann, B. R., Boehm, B. O., & März, W.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-02-13
- Volume
- 36
- Issue
- 3
- Pages
- 708-714
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2099682683
- Cited by
- 41
- References
- 3
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.